Immune checkpoint inhibitor therapy for ACTH-secreting pituitary carcinoma: a new emerging treatment?

BACKGROUND: Pituitary carcinomas are rare but aggressive and require maximally coordinated multimodal therapies. For refractory tumors, unresponsive to temozolomide (TMZ), therapeutic options are limited. Immune checkpoint inhibitors (ICI) may be considered for treatment as illustrated in the presen...

Descripción completa

Detalles Bibliográficos
Autores principales: Sol, Bastiaan, de Filette, Jeroen M K, Awada, Gil, Raeymaeckers, Steven, Aspeslagh, Sandrine, Andreescu, C E, Neyns, Bart, Velkeniers, Brigitte
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2020
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7707801/
https://www.ncbi.nlm.nih.gov/pubmed/33112279
http://dx.doi.org/10.1530/EJE-20-0151

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7707801/
https://www.ncbi.nlm.nih.gov/pubmed/33112279
http://dx.doi.org/10.1530/EJE-20-0151

Ejemplares similares